Sun Pharmaceutical gains on USFDA nod for Ximino
The approval is for XiminoTM (Minocycline HCl) extended-release capsules 45 mg, 90 mg and 135 mg.
)
A man carrying a gas cylinder walks out of the research and development centre of Sun Pharmaceutical Industries Ltd in Mumbai
Shares of Sun Pharmaceutical were up over 3% after the company announced that the US Food and Drug Administration (USFDA) has approved its supplemental new drug application for XiminoTM (Minocycline HCl) extended-release capsules
45 mg, 90 mg and 135 mg.
XiminoTM extended-release capsules are indicated for inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older, Sun Pharmaceutical said in a release.
This approval further strengthens the Company’s branded dermatology portfolio in the US. It expects XiminoTM extended-release capsules to be available for patients during the fourth quarter of 2015, the release added.
The stock opened at Rs 948 and touched a high of Rs 961. At 9:55AM, over 2.1 million shares were traded on both the stock exchanges.
Don't miss the most important news and views of the day. Get them on our Telegram channel
First Published: Aug 20 2015 | 9:55 AM IST